Regulation of NHE3 by the mTOR/autophagy pathways in diarrheal diseases
腹泻疾病中 mTOR/自噬途径对 NHE3 的调节
基本信息
- 批准号:8677889
- 负责人:
- 金额:$ 7.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAcuteAffectAnimalsAutophagocytosisAutophagosomeBiogenesisBody Weight decreasedBrush BorderCatabolic ProcessCell ProliferationCell physiologyCellsCessation of lifeChronicDataDevelopmentDiarrheaDiseaseDown-RegulationEpithelial CellsEventExocytosisFecesGenesGenetic TranscriptionHospitalizationHumanHydrogenImmunosuppressive AgentsIncidenceInfectionIntestinesKnock-outLaboratoriesMediatingMembrane Transport ProteinsMusNutrientOrganOrgan TransplantationOrganellesPathway interactionsPatientsProtein-Serine-Threonine KinasesProteinsQuality of lifeRattusRecyclingRegulationReportingRiskRoleSecondary toSerumSirolimusSmall IntestinesSodiumSurfaceSystemTranslationsTransplant RecipientsUbiquitinationWaterWorkabsorptionapical membranecell growthcell typeexperienceinsightintestinal villimTOR proteinmouse modelnovelnovel therapeuticspublic health relevancereceptortraffickingvillin
项目摘要
DESCRIPTION (provided by applicant): Chronic diarrhea and weight loss with episodic profound acute diarrhea frequently occur in organ transplant recipients related to the use of immunosuppressants. Severe forms of diarrhea require multiple hospitalizations, which are costly, affect patients' quality of life and significantly increase the risk of graft loss and patint death. Sirolimus (rapamycin) is frequently used as an immunosuppressant in organ transplantations. The incidence of diarrhea related to rapamycin use varies from 25% to 42%. Among the various causes of diarrhea (e.g., infection), a significant portion of organ recipients experience diarrhea associated with the use of rapamycin without a clear cause. It is therefore of paramount importance to understand the mechanisms underlying rapamycin-induced diarrhea. Rapamycin's action is mediated by inhibiting the mammalian Target of Rapamycin pathway (mTOR). Inhibition of mTOR by rapamycin stimulates autophagy activity. Thus, the mTOR and autophagy pathways are strong candidates for mediating rapamycin- induced diarrhea, but the exact mechanism of mTOR and/or autophagy in diarrheal disease remains entirely unclear. The brush border Na+/H+ exchanger 3 (NHE3), primarily residing at the apical membrane in the intestine, is known to be responsible for the majority of Na and water absorption. Deletion of NHE3 is sufficient to cause diarrhea. We thus hypothesize that rapamycin treatment alters the mTOR and autophagy pathways, which in turn impinge on NHE3, resulting in diarrhea. Indeed, our preliminary data demonstrated a direct role of suppression of NHE3 by rapamycin in diarrheal patients as well as in animals. The objective of this proposal is to use genetically modified mouse models to further pinpoint if NHE3 regulation by rapamyicn is mediated by the mTOR and autophagy pathways in intestinal epithelial cells. We will use the intestinal epithelial cell- specific mTOR and Atg7 knockout (mTOR-/- and Atg7-/-) mice, with which we will ask if NHE3 expression is altered in mTOR-/- and Atg7-/- mice (Aim IA and IIA) and if rapamycin loses its effect in mTOR-/- and Atg7-/- mice (Aim IB and IIB). The results from this proposal could provide new insights into the roles of the mTOR and autophagy pathways in regulation of the apical membrane transporter NHE3, and may aid in the development of new therapeutic strategies for diarrheal diseases.
描述(由申请方提供):慢性腹泻和体重减轻伴阵发性严重急性腹泻常发生在与使用免疫抑制剂相关的器官移植受者中。严重的腹泻需要多次住院治疗,这是昂贵的,影响患者的生活质量,并显着增加移植物丢失和患者死亡的风险。西罗莫司(雷帕霉素)经常被用作器官移植中的免疫抑制剂。与雷帕霉素使用相关的腹泻发生率从25%到42%不等。在腹泻的各种原因中(例如,感染),很大一部分器官接受者经历与使用雷帕霉素相关的腹泻,而没有明确的原因。因此,了解雷帕霉素诱导腹泻的机制至关重要。雷帕霉素的作用是通过抑制哺乳动物雷帕霉素靶途径(mTOR)介导的。雷帕霉素对mTOR的抑制刺激自噬活性。因此,mTOR和自噬途径是介导雷帕霉素诱导的腹泻的强有力的候选者,但mTOR和/或自噬在腹泻病中的确切机制仍然完全不清楚。刷状缘Na+/H+交换器3(NHE 3)主要位于肠的顶膜,已知其负责大部分Na和水的吸收。NHE 3的缺失足以引起腹泻。因此,我们假设雷帕霉素治疗改变了mTOR和自噬途径,这反过来又影响了NHE 3,导致腹泻。事实上,我们的初步数据证明了雷帕霉素对NHE 3的抑制在牙周炎患者和动物中的直接作用。该提案的目的是使用遗传修饰的小鼠模型来进一步确定雷帕霉素对NHE 3的调节是否由肠上皮细胞中的mTOR和自噬途径介导。我们将使用肠上皮细胞特异性mTOR和Atg 7敲除(mTOR-/-和Atg 7-/-)小鼠,我们将询问在mTOR-/-和Atg 7-/-小鼠中NHE 3表达是否改变(Aim IA和IIA)以及雷帕霉素在mTOR-/-和Atg 7-/-小鼠中是否失去其作用(Aim IB和IIB)。该提案的结果可以为mTOR和自噬途径在调节顶端膜转运蛋白NHE 3中的作用提供新的见解,并可能有助于开发新的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xinjun Zhu其他文献
Xinjun Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xinjun Zhu', 18)}}的其他基金
Regulation of NHE3 by the mTOR/autophagy pathways in diarrheal diseases
腹泻疾病中 mTOR/自噬途径对 NHE3 的调节
- 批准号:
8571408 - 财政年份:2013
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
8627234 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
7953165 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
8731199 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
8545825 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
8135315 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
NHE3 Polymorphisms and Chronic Diarrheal Diseases
NHE3 多态性与慢性腹泻病
- 批准号:
8330896 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 7.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 7.9万 - 项目类别:
Operating Grants